	US 12,466,826 B2
	3-benzoyl-1H-pyrrolo[2,3-b]pyridine derivatives as MKK4 inhibitors for treating liver diseases
Roland Selig, Munich (DE); Stefan Laufer, Tübingen (DE); and Wolfgang Albrecht, Ulm (DE)
Assigned to HEPAREGENIX GMBH, Tübingen (DE)
Appl. No. 17/792,685
Filed by HepaRegeniX GmbH, Tübingen (DE)
PCT Filed Jan. 13, 2021, PCT No. PCT/EP2021/050527 § 371(c)(1), (2) Date Jul. 13, 2022, PCT Pub. No. WO2021/144287, PCT Pub. Date Jul. 22, 2021.
Claims priority of application No. 20151929 (EP), filed on Jan. 15, 2020.
Prior Publication US 2023/0088395 A1, Mar. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61K 31/437 (2006.01)

CPC C07D 471/04 (2013.01)

13 Claims

1. A compound having formula (I)

wherein

R¹is H or alkyl;

R²is H or alkyl;

R⁴is H, or alkyl;

R⁶is H, or alkyl;

R^wis —NR¹⁰SO₂R¹²;

R¹⁰is H, alkyl, or phenylalkyl;

R¹²is H, alkyl, or phenylalkyl, wherein the phenyl group is optionally substituted with 1 or 2 groups independently selected from alkyl and halogen;

R^x, R^y, R^zand R^zzare selected from:

a) R^xand R^yare F and R^zand R^zzare H; and

b) R^x, R^yand R^zzare F and R^zis H;

R⁵is selected from

(a) phenyl which is substituted with 1, 2 or 3 groups independently selected from

—POdi(alkyl), and

hydroxyalkyl-ONH—CO—;

alkyl,

cycloalkyl,

alkoxy, and

alkylsulfanyl,

or a pharmaceutically acceptable salt or optical isomer thereof.